Introduction
Persistent gastric colonization with the human pathogen Helicobacter pylori causes chronic active gastritis in infected individuals and has been linked epidemiologically to gastric and duodenal ulcers, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer. [1] [2] [3] The chronic gastric inflammation induced by H. pylori infection constitutes a prerequisite for the formation of preneoplastic and malignant lesions, both in humans and in rodent models of Helicobacter induced disease. 4, 5 The transformation from normal mucosa to gastric cancer occurs via a sequence of precursor lesions starting with atrophic gastritis, intestinal metaplasia and dysplasia. The two processes of inflammation and carcinogenesis share a common molecular mediator, the cyclooxygenase enzymes. The COX-1 isoform is constitutively expressed in most cell types whereas COX-2 is induced in response to proinflammatory stimuli such as LPS, IL-1 and TNF-. 8 The most important lipid product of COX-2, prostaglandin E 2 (PGE 2 ), exerts its effects by binding to the E-prostanoid receptors [1] [2] [3] [4] (EP1-4), which are expressed ubiquitously in most murine tissues. 9 
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Several lines of evidence indicate that COX-2-dependent pathways play a role in carcinogenesis, especially in the gastro-intestinal tract. Many solid tumors overexpress COX-2/PGE 2 , and polymorphisms in the COX-2 regulatory region determine the carrier's risk of developing several epithelial cancers. 10, 11 The long term low-level intake of nonsteroidal anti-inflammatory drugs (NSAIDs) inhibiting COX activity reduces the risk for colorectal cancer 12, 13 as well as gastric cancer.
14 Tumor-derived PGE 2 is believed to promote cancer progression by stimulating cell motility/invasion and tumor-associated angiogenesis and by preventing tumor cell apoptosis (reviewed in 15, 16 ). Several pathways and signalling networks are activated or enhanced by PGE 2 ; most notably, PGE 2 potentiates Wnt and PPAR signalling to induce target genes involved in replication and survival and triggers cell migration by activation of the EGFR pathway. 15 In addition to its direct effects on cancer cell biology, PGE 2 is known to have strong immunosuppressive effects, giving rise to the hypothesis that PGE 2 production may allow tumors to evade immune surveillance. 17 The reported immunosuppressive effects of PGE 2 on CD4 + T-cells, in particular Th1-polarized effector T-cells (reviewed in 18 ), prompted us to examine the role of COX-2/PGE 2 in our model of Helicobacter-induced, T-cell-driven gastric preneoplasia. We found that inhibition of COX-2 enzymatic activity strikingly accelerated the development of gastritis and premalignant gastric lesions, and that, conversely, systemic administration of synthetic PGE 2 prevented premalignant changes. The protective effects of PGE 2 in our model could be attributed to its immunosuppressive effects on CD4 + CD25 -T-cells, which failed to migrate, to proliferate and to secrete IFN-when exposed to PGE 2 in vitro or in vivo. Taken together, the data suggest that COX-2/PGE 2 dependent pathways are critical
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Materials and Methods
Mice, cell culture, bacterial infections and vaccination
Male C57BL/6, IL-10 -/-BL/6 and Ly5.1BL/6 mice (Charles River Laboratories, Sulzfeld, Germany) were bred at a Helicobacter-free SPF facility and infected at 5-6 weeks of age.
All animal experiments were approved by the cantonal veterinary office. Helicobacter strains used for animal experimentation were H. felis CS1 (ATCC 49179) 19 and H. pylori strain SS1. 20 Mouse infections were performed orally with ~10 8 bacteria. Primary gastric epithelial cells were isolated as previously described; 21 the immortalized murine gastric epithelial cell line used in this study was also described previously. 7 Both cell types were grown in DMEM/Ham's F12 medium (1:1; Gibco) supplemented with 10% FCS and infected for 12 hours with H. pylori strains G27 or an isogenic mutant lacking the Cag pathogenicity island (PAI), G27 PAI.
22
Vaccination of mice was performed as stated in the supplemental methods.
Pharmacological treatments
For inhibition of COX-2, mice were fed a diet supplemented with 1500 ppm Celecoxib 
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Preparation of gastric tissue and assessment of colonization, gastric IFN-production,
Cox-2 expression, neutrophil infiltration and histopathology
After sacrifice, the stomachs were dissected longitudinally into equally sized pieces. For the assessment of H. felis colonization, total genomic stomach DNA was subjected to quantitative PCR analysis of the flaB gene, as described previously. 7 Quantitative analysis of gastric IFN-expression and Cox-2 expression and activity was performed as described in the supplemental methods. Neutrophil infiltration was quantified as described.
7
Paraffin sections were stained with the histological dyes Giemsa, Alcian Blue (AB) and Periodic acid Schiff (PAS) as well as an antibody specific for proliferating cell nuclear antigen (PCNA; clone PC10, Zymed Labs) for grading of gastric histopathology based on the features described in the updated Sydney classification (see Suppl.
Methods). 
Statistical analysis
P-values were calculated using Graph Pad prism 5.0 software. The significance of differences in histopathology scores was calculated by Mann-Whitney test and the significance of numerical differences was calculated by Student's t-test. All in vitro assays were analyzed in triplicate and are shown with standard deviations.
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Results
Helicobacter infection induces cyclooxygenase-2 (COX-2) and PGE 2 in vitro and in vivo
To assess whether COX-2 and its product PGE 2 are induced upon Helicobacter infection in cell culture models, we infected primary murine gastric epithelial cells ( Figure 1A ) and immortalized murine gastric epithelial cells ( Figure 1B ) with wild type H. pylori G27 or an isogenic mutant ( PAI) lacking the Cag pathogenicity island, a known virulence determinant of pathogenic H. pylori strains.
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In both cell types, COX-2 protein expression and PGE 2 secretion was induced by H. pylori in a dose-dependent manner, and independently of the Cag PAI ( Figure 1A -C). PGE 2 production was blocked in the presence of the COX inhibitor indomethacin ( Figure 1C ), indicating that it is produced exclusively by COX enzymes in this setting. COX-2 and its product PGE 2 were further also strongly induced in the gastric mucosa of infected compared to uninfected mice ( Figure 1D and E).
In order to determine whether mucosal PGE 2 concentrations correlate with the degree and type of gastric pathology in our model, we selected groups of Helicobacter-infected mice based on their predominant pathology. We thus compared mice that showed either gastritis, hyperplasia or acidic mucus-positive metaplasia, respectively (for simplicity referred to as "metaplasia" in the following; Figure 1F ). PGE 2 production was significantly higher in animals displaying epithelial damage, e.g. hyperplasia and metaplasia, compared to those which showed gastritis only ( Figure 1F ). Our data are consistent with previous studies reporting COX-2 expression in H. pylori-infected cultured epithelial cells, 24 and in gastric preneoplastic and malignant lesions.
25
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COX-2 inhibition during infection aggravates
Treatment of Helicobacter-infected mice with synthetic PGE 2 inhibits chronic inflammation and pre-cancerous lesions
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To investigate a possible protective effect of COX-2 activity on the H. felis-infected gastric mucosa in an independent experimental setup, we treated C57BL/6 mice with synthetic PGE 2 during 6 or 12 weeks of infection ( Figure 3A ). To ensure complete activation of all PGE 2 receptors (EP1-4), we administered a mixture of two synthetic PGE 2 analogs, 16,16-dimethyl PGE 2 and 17-phenyl trinor PGE 2 (referred to in the following as "PGE 2 "). The PGE 2 treatment prevented the mild to moderate lymphocytic infiltration observed after 6 weeks post infection (p.i.; Figure 3A and B) and also completely inhibited the moderate to severe chronic inflammation, atrophy, metaplasia and/or hyperplasia indicative of 12 week-infected mice ( Figure 3A and C).
Immunohistochemical staining and quantification of proliferating cell nuclear antigen (PCNA) reactivity further confirmed the efficient inhibition of epithelial hyperproliferation by PGE 2 ( Figure 3D ). Consequently, the decrease in H. felis colonization that typically accompanies the onset of severe gastric pathology between 6 and 12 weeks post infection was prevented by PGE 2 treatment ( Figure 3E ). Long term treatment with PGE 2 further completely prevented the increase in local IFN-production that typically occurs in this time frame ( Figure 3F ) and that precedes the onset of pathology and leads to the observed reduction of the bacterial burden. 
Pre-existing gastric cancer precursor lesions in H. felis infected mice can be reversed by PGE 2 treatment
To test the effects of PGE 2 as a potential therapeutic agent capable of curing pre-existing lesions, we infected mice with H. felis for 3 months and verified the efficient induction of preneoplastic pathology in a small control group (data now shown). 5 of the remaining 13 mice received PGE 2 for another month ( Figure 5A ). Interestingly, this treatment efficiently reversed pre-existing lesions, reducing the scores of all histopathological parameters ( Figure 5A and B) and the fraction of corpus area affected by PCNA-positive hyperplasia ( Figure 5C ) as well as neutrophil infiltration ( Figure 5D ). As in prophylactically treated mice, PGE 2 had a beneficial, in this case even curative, effect on mucosal integrity while at the same time boosting bacterial colonization ( Figure 5E ). In line with all previous results ( Figures 3 and 4) , the PGE 2 treatment significantly reduced the local gastric expression of IFN-( Figure 5F ).
To confirm the regression of pre-existing lesions upon PGE 2 treatment during the last of 4 months of H. felis infection, we repeated the experiment with 3 additional read outs (Suppl. Figure 1 ). As before, the lesions regressed in all PGE 2 could be blocked at least partially by PGE 2 treatment (Suppl. Figure 1C ). We conclude from both studies that systemically administered PGE 2 efficiently reverses pre-existing gastric cancer precursor lesions, possibly by blocking the priming and activity of Th1-polarized T-cell responses in the draining lymph nodes.
PGE 2 impairs vaccine-induced protection against Helicobacter by blocking local effector T-cell responses
We have shown in the experiments outlined above that PGE 2 Figure 6D ). Taken together, our data imply that PGE 2 interferes with the T-cell mediated control of Helicobacter infection not only under standard experimental infection conditions, but also during a challenge infection after vaccination, and that this effect is due to T-cell inhibition in vivo.
To test whether PGE 2 directly interferes with IFN-production by MLN cells, single cell suspensions were cultured in the presence of increasing concentrations of PGE 2 ( Figure   6E ). PGE 2 treatment reduced the infection-dependent secretion of IFN-into the supernatant by on average 43% and 94% at a low and high dose, respectively ( Figure   6E ). We conclude that PGE 2 efficiently blocks the production of IFN-both in vitro and in vivo, which may explain why PGE 2 -treated mice are protected from IFN--induced preneoplastic pathology and show impaired bacterial clearance, a finding that is consistent with our previous report of an inverse link between colonization and pathology. We therefore asked whether the first step in this cascade, the transcriptional activation of the IL-2 gene, could be blocked by PGE 2 . Indeed, PGE 2 treatment efficiently inhibited IL-2 and IFNG gene expression induced by CD3/CD28 crosslinking ( Figure 7E ). Therefore, we tested whether adding recombinant IL-2 would reverse the effects of PGE 2 . Indeed, addition of IL-2 was able to completely reverse the effects of PGE 2 on T-cell activation, proliferation and IFNsecretion ( Figure 7C, D) . These results suggest that PGE 2 inhibits T-cells at least in part by interfering with their autocrine IL-2-driven positive feedback loop.
Based on studies reporting that PGE 2 may act as an immunosuppressant by stimulating the suppressive activities of regulatory T-cells, 28 we speculated that Tregs might be an additional target of PGE 2 in the control of T-cell-mediated immunopathology in the Helicobacter-infected stomach. To examine this possibility, we pre-conditioned
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Recombinant IL-2 reverses the effects of PGE 2 in vivo
In order to investigate whether the observed opposing effects of IL-2 and PGE 2 hold true in vivo, and to explore whether T-cells are indeed critical targets of PGE 2 , we utilized the above-mentioned IL-10 -/-model ( Figure 4) . In addition to a group treated with PGE 2 only, we also included groups that received i.p. doses of recombinant IL-2 (4x10 4 units, 3
times weekly) together with PGE 2 , or IL-2 alone ( Figure 7F ). IL-2 administration efficiently reversed the protection from gastric pathology conferred by PGE 2 ( Figure 7F ).
This result suggests that the protective effect of PGE 2 on the infected gastric mucosa is due to the suppression of T-cell effector functions, which are known to directly trigger the atrophic gastritis, hyperplastic and metaplastic transformation that are a hallmark of the infection in mice as well as in humans.
7
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Discussion
In this study we provide experimental evidence that COX-2/PGE 2 -dependent pathways play an important immunomodulating role during the early stages of Helicobacterinduced gastric pathogenesis, thereby preventing excessive gastric immunopathology. We show that systemic administration of PGE 2 prevented, and COX-2 inhibition exacerbated,
Helicobacter-induced atrophic gastritis, epithelial hyperplasia and metaplasia. These effects were due to the immunosuppressive effects of PGE 2 on T-cells, which failed to proliferate and to secrete IL-2 and IFN-when exposed to PGE 2 in vitro or in vivo.
Our data are in line with several previous studies reporting exacerbated gastritis in H.
pylori-infected rodents under conditions of COX-1 or -2 inhibition or deletion of the
COX-1 or -2 genes.
29-32
Similar effects were observed in human trials investigating the effects of COX inhibition by aspirin in H. pylori infected, asymptomatic individuals, who suffered significantly more from mucosal injury and peptic ulcers than their uninfected counterparts.
33, 34
Despite the well-documented side effects of aspirin use on the gastric mucosa, the longterm, low level use of aspirin or non-aspirin NSAIDs prevents the development of gastric cancer; this association holds true even in a large meta-analysis including a total of 9 studies.
14 Similarly, treatment with the COX inhibitor nimesulide prevented a substantial portion of chemically induced gastric cancers in H. pylori-infected mice. 35 The chemopreventive outcome of COX inhibition in studies examining cancer as the end point is generally believed to be due to the powerful effects of tumor-derived PGE 2 on cancer cell survival and invasion, tumor-associated angiogenesis and on anti-tumor immunosuppression, all of which promote cancer progression.
15
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We demonstrate here that T-cells, in particular effector subsets of the T-helper compartment, can be targeted by PGE 2 . We have shown in a previous study that An intriguing finding of our study was the observed therapeutic effect of PGE 2 on preexisting lesions, an observation that is seemingly incongruent with studies reporting the prevention of gastric cancer by COX inhibition. 14, 35 However, it has to be stressed that Helicobacter-associated preneoplastic lesions in our mouse models are benign and can at least partially be reversed upon antibiotic eradication of the infection. 38 Under these circumstances, the beneficial effect of PGE 2 's suppression of pathogenic T-cells apparently outweighs the potential pro-carcinogenic effects that PGE 2 may have on gastric epithelial cells themselves. 32 In conclusion, our data is consistent with a protective role for PGE 2 during the early stages of the Helicobacter-induced gastric carcinogenesis sequence; at the molecular level, PGE 2 blocks the autocrine IL-2-driven positive feedback loop to prevent T-cell effector functions that are required both for Helicobacter clearance and for the induction of preneoplastic gastric immunopathology.
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Figure legends 
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Supplemental methods
Assessment of gastric histopathology
Paraffin sections were stained with the histological dyes Giemsa, Alcian Blue and Periodic acid Schiff as well as an antibody specific for proliferating cell nuclear antigen (PCNA; clone PC10, Zymed Labs) for grading of gastric histopathology based on the features described in the updated Sydney classification. 
Pharmacological treatments (extended version)
For inhibition of COX-2, mice were fed a diet supplemented with 1500 ppm Celecoxib (D04090202) as described by Jacobi et al.
3
(Research Diets, New Brunswick, NJ, USA)
or an identical control diet (AIN 76A D1000) without the active compound. The average daily drug dose per mouse was determined to be 3.7mg based on the quantification of food intake per cage. For PGE 2 treatment in vivo and in vitro, a stock containing 1mg/ml 16,16-dimethyl PGE 2 and 1mg/ml 17-phenyl trinor PGE 2 was prepared in 100% ethanol, as described by Hansen-Petrik et al. 4 . To this end, the methyl acetate in which PGE 2 is commercially available had to be vacuum-evaporated and then reconstituted in ethanol.
The stock solution was diluted to 10 g/100 l in PBS and injected twice intraperitoneally 
Preparation of protein extracts for COX-2 and PGE 2 quantification
Protein extracts of scraped gastric mucosa were prepared by homogenization in extraction buffer (20mM HEPES, 0.4mM NaCl, 25% glycerol, 1mM EDTA, 1mM NaF
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Transwell migration assay
CD4
